IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ODICINO, Franco Edoardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.798
EU - Europa 4.223
AS - Asia 1.745
OC - Oceania 47
AF - Africa 35
SA - Sud America 29
Continente sconosciuto - Info sul continente non disponibili 5
Totale 12.882
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.720
IT - Italia 1.823
CN - Cina 733
UA - Ucraina 625
PL - Polonia 463
SG - Singapore 358
DE - Germania 329
HK - Hong Kong 237
GB - Regno Unito 210
FI - Finlandia 195
TR - Turchia 166
CH - Svizzera 138
IE - Irlanda 136
IN - India 88
FR - Francia 77
CA - Canada 60
EE - Estonia 49
ID - Indonesia 48
AU - Australia 39
SE - Svezia 28
VN - Vietnam 28
ES - Italia 25
NL - Olanda 22
JP - Giappone 17
BD - Bangladesh 16
LI - Liechtenstein 13
MX - Messico 12
AR - Argentina 11
RU - Federazione Russa 11
BE - Belgio 10
CZ - Repubblica Ceca 9
PH - Filippine 9
MY - Malesia 8
NZ - Nuova Zelanda 8
MK - Macedonia 7
PT - Portogallo 7
SK - Slovacchia (Repubblica Slovacca) 7
BG - Bulgaria 6
BR - Brasile 6
IR - Iran 6
LU - Lussemburgo 6
PK - Pakistan 6
AT - Austria 5
DK - Danimarca 5
EU - Europa 5
NG - Nigeria 5
ZA - Sudafrica 5
EC - Ecuador 4
KR - Corea 4
MU - Mauritius 4
PE - Perù 4
SA - Arabia Saudita 4
UG - Uganda 4
AZ - Azerbaigian 3
BS - Bahamas 3
EG - Egitto 3
GH - Ghana 3
GR - Grecia 3
JO - Giordania 3
LT - Lituania 3
RS - Serbia 3
TH - Thailandia 3
AL - Albania 2
CL - Cile 2
CO - Colombia 2
DZ - Algeria 2
ET - Etiopia 2
GT - Guatemala 2
IQ - Iraq 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MA - Marocco 2
MG - Madagascar 2
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
LK - Sri Lanka 1
LY - Libia 1
MS - Montserrat 1
NO - Norvegia 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
TZ - Tanzania 1
UZ - Uzbekistan 1
Totale 12.882
Salva come PNG Salva come JPEG
Città #
Fairfield 913
Woodbridge 768
Ashburn 582
Houston 474
Warsaw 453
Jacksonville 442
Wilmington 382
Seattle 373
Chandler 344
Ann Arbor 338
Cambridge 322
Singapore 290
Princeton 239
Hong Kong 232
New York 178
Dearborn 168
Nanjing 156
Dublin 136
Brescia 134
Istanbul 133
Milan 132
Helsinki 113
Beijing 98
Zurich 83
London 79
Los Angeles 61
Rome 60
Shanghai 57
Boardman 55
Des Moines 53
Nanchang 49
Tallinn 49
Shenyang 48
Chicago 45
Hebei 40
San Diego 40
Changsha 38
Jakarta 36
Toronto 34
Jinan 31
Jiaxing 29
Kunming 24
Tianjin 24
Munich 23
Romola 22
Dong Ket 20
Hangzhou 19
San Francisco 19
Washington 18
Frankfurt am Main 17
Melbourne 17
Pune 17
Pleasanton 16
Orange 15
Turin 14
Dalmine 13
Cedar Knolls 12
Dhaka 12
Haikou 12
Paris 12
Verona 12
Hefei 11
Lancaster 11
Brussels 10
Giubiasco 10
Guangzhou 10
Lanzhou 10
Sydney 10
Zhengzhou 10
Genoa 9
Taizhou 9
Bergamo 8
Jonesboro 8
Kocaeli 8
Madrid 8
Boisar 7
Buffalo 7
Kilburn 7
Leganés 7
Norwalk 7
Tokyo 7
Dubendorf 6
Monmouth Junction 6
Ningbo 6
Osimo 6
Phoenix 6
Sofia 6
Southwark 6
Taiyuan 6
Abuja 5
Auckland 5
Bari 5
Berlin 5
Canberra 5
Dallas 5
Florence 5
Fuzhou 5
Leawood 5
Luxembourg 5
Mariano Comense 5
Totale 8.902
Salva come PNG Salva come JPEG
Nome #
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study 2.259
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 288
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 264
Claudin3 is localized outside the tight junctions in human carcinomas 233
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 226
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 157
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 150
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 148
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 144
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 139
Consolidation therapies revisited: weekly paclitaxel 134
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 132
null 132
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 130
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 129
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 128
Carcinoma of the Fallopian tube 127
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 123
Role of 18F-FDG PET/CT in restaging and follow-up of patients with uterine sarcomas 123
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 122
Preeclampsia and late fetal growth restriction 116
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 115
Replacement therapy for breast cancer survivors. A pilot study 114
Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum 114
Gestational trophoblastic diseases 113
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines 111
Clinical and prognostic value of 18 F-FDG PET/CT in recurrent endometrial carcinoma 111
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study 110
Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study 110
Carcinoma of the Fallopian tube 108
Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium 106
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers 106
Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience 104
History of the FIGO cancer staging system 103
Parametrial endometriosis with ureteral involvement: A case report of a conservative approach without ureteral resection 103
Staging classification for cancer of the ovary, fallopian tube, and peritoneum 103
New development of the FIGO staging system. 102
Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium 102
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer 102
Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer? 101
Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium. 101
Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens 101
Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity 100
Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy 100
Early stage ovarian cancer: the Italian contribution to clinical research. An update 99
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 98
Hormone replacement therapy in breast cancer 98
Interval debulking surgery in advanced epithelial ovarian cancer 97
Gestational trophoblastic diseases 97
Optimizing gemcitabine regimens in ovarian cancer. 96
Revised FIGO staging for carcinoma of the cervix. 96
Five-year follow-up of placental involution after abdominal pregnancy 96
Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. 95
Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 94
Uterine sarcomas: a clinicopathologic study 93
Crossover study with cisplatin or carboplatin in advanced ovarian cancer 93
Carcinoma of the corpus uteri 93
Staging of gynecologic malignancies 92
Role of HPV DNA, HPV mRNA and cytology in the follow-up of women treated for cervical dysplasia. 92
Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology 92
Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship 91
Ovarial cancer: best timing and applications of debulking surgery 90
Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 89
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro 88
Carcinoma of the corpus uteri 87
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 87
Carcinoma of the vulva 86
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy 85
Carcinoma of the vagina 83
Carcinoma of the vagina 82
Carcinoma of the fallopian tube. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 80
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. 80
Cancer in women 77
Carcinoma of the cervix uteri 77
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 77
Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 76
Surgery of advanced malignant epithelial tumours of the ovary 76
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 76
Carcinoma of the ovary 75
Carcinoma of the ovary 75
Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group) 74
The treatment of progressive ovarian carcinoma with D-Trp-LHRH (Decapeptyl). Gruppo Oncologico Nord ovest (GONO) 73
Carcinoma of the cervix uteri 71
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic 64
Carcinoma of the vulva. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 62
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 62
Carcinoma of the vulva 61
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 61
Gestational trophoblastic neoplasia. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 59
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study 58
The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features 57
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study 57
Cervical cancer staging 55
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 55
Carcinoma of the vagina. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. 54
HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. 54
Uterine cervix dysplasias and viral implications 53
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 48
Management of Large Pediatric and Adolescent Ovarian Neoplasms with a Leak-Proof Extracorporeal Drainage Technique: Our Experience Using a Hybrid Minimally Invasive Approach 44
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study 41
Totale 12.165
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.831
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.831
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.766 0 0 0 0 160 349 315 285 189 274 57 137
2020/20211.567 37 161 45 180 78 169 67 188 159 271 136 76
2021/20221.018 64 157 6 43 3 51 105 70 48 122 96 253
2022/20232.139 159 59 207 274 229 283 67 148 193 128 211 181
2023/20242.370 177 106 201 159 209 375 137 183 361 245 45 172
2024/2025990 42 113 96 471 268 0 0 0 0 0 0 0
Totale 13.327